|Traded as||SIX: NOVN, NYSE: NVS|
|Founded||1996 (from merger)|
|Headquarters||Basel, Basel-Stadt, Switzerland|
|Key people||Joerg Reinhardt (Chairman), Joseph Jimenez (CEO)|
|Products||Pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health (list...)|
|Revenue||US $58.566 billion (2011)|
|Operating income||US $10.998 billion (2011)|
|Net income||US $9.245 billion (2011)|
|Total assets||US $117.496 billion (2011)|
|Total equity||US $65.940 billion (2011)|
|Employees||119,418 (FTE, end 2010)|
|Subsidiaries||Ciba Vision, Sandoz, Alcon, Chiron Corporation|
Novartis manufactures such drugs as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan) and imatinib mesylate (Gleevec/Glivec). Additional agents include cyclosporin (Neoral/Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others.
In 1996 Ciba-Geigy merged with Sandoz, with the pharmaceutical and agrochemical divisions of both staying together to form Novartis. Other Ciba-Geigy and Sandoz businesses were sold off, or, like Ciba Specialty Chemicals, were spun off as independent companies. The Sandoz brand disappeared for 3 years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Novartis divested its agrochemical and genetically modified crops business in 2000 with the spinout of Syngenta, in partnership with AstraZeneca which also divested its agrochemical business.
Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA).
- 1 Corporate structure
- 2 Place in its market segments
- 3 History
- 4 Research
- 5 Basel headquarters campus redesign
- 6 Products
- 7 Controversies and criticism
- 8 See also
- 9 References
- 10 External links
Novartis AG is a Swiss, publicly traded, holding company that operates through the Novartis Group; Novartis AG owns, directly or indirectly, all companies worldwide that operate as subsidiaries of the Novartis Group.:117
The businesses of Novartis are divided into six operating divisions: Pharmaceuticals, Alcon (eye care), Vaccines and Diagnostics, Sandoz (generics), Consumer (divided into two divisions: Over-the-Counter and Animal Health), and Corporate.:150 Novartis operates directly and through dozens of subsidiaries in countries around the world, each of which fall under one of the divisions, and that Novartis categorizes as fulfilling one or more of the following functions: "Holding/Finance: the entity is a holding company and/or performs finance functions for the Group; Sales: the entity performs sales and marketing activities for the Group; Production: the entity performs manufacturing and/or production activities for the Group; and Research: the entity performs research and development activities for the Group.":251–253
Novartis AG also holds 33.3% of the shares of Roche however, it does not exercise control over Roche. Novartis also owns 24.9% of Idenix Pharmaceuticals but, again, does not exercise control over Idenix.:117 Novartis also has two significant license agreement with Genentech, a subsidiary of Roche. One agreement is for Lucentis; the other is for Xolair, both of which Novartis markets outside the US.:239
Place in its market segments
Overall, Novartis was the world's second largest pharmaceutical company in 2011, and was projected to take first place in 2018. An IMS Health report ranked Novartis as the biggest pharma company in 2012.
Alcon: Alcon was already the world's largest and most profitable eye care company when Novartis bought it, with 2009 annual sales of $6.5 billion and net income of $2 billion. At that time, Novartis stated that it believed the two companies could generate approximately $200 million of potential annual pre-tax cost synergies.
Sandoz: As of 2013[update], Sandoz was the world's second largest generic drug company, contributing US$1.09 billion to Novartis' operating profit on US$8.70 billion in revenue in 2012. Sandoz' biosimilars leads its field, getting the first biosimilar approvals in the EU.
Vaccines and Diagnostics: As of 2013[update] Novartis was considering selling this division off. While "sales in the unit were up 14% for the first half of 2013, it reported an operating loss of $240 million in the first half of 2013 after a $250 million loss for all 2012.... Vaccine revenue was $1.4 billion in 2012 and has been forecast to more than double to $3.14 billion by 2018."
Consumer: Novartis is not a leader in the over the counter or animal health segments; its leading OTC brands are Excedrin and Theraflu, but sales have been slowed by problems at its key US manufacturing plant.
In 2012, Novartis ranked 7th on the Access to Medicine Index,:88 which "ranks companies on how readily they make their products available to the world’s poor." In 2010, Novartis was in the top three pharma companies (as it was in 2008).
Novartis was created in 1996 from the merger of Ciba-Geigy and Sandoz Laboratories, both Swiss companies with long histories. Ciba-Geigy was formed in 1970 by the merger of J. R. Geigy Ltd (founded in Basel in 1758) and CIBA (founded in Basel in 1859). Combining the histories of the merger partners, the company's effective history spans 250 years.
In 1859, Alexander Clavel (1805–1873) took up the production of fuchsine in his factory for silk-dyeing works in Basel. In 1864, a new site for the production of synthetic dyes was constructed, and in 1873, Clavel sold his dye factory to the new company Bindschedler and Busch. In 1884, Bindschedler and Busch was transformed into a joint-stock company with the name "Gesellschaft für Chemische Industrie Basel" (Company for Chemical Industry Basel). The acronym, CIBA, was adopted as the company's name in 1945.
Johann Rudolf Geigy-Gemuseus (1733–1793) began trading in 1758 in "materials, chemicals, dyes and drugs of all kinds" in Basel, Switzerland. Johann Rudolf Geigy-Merian (1830–1917) and Johann Muller-Pack acquired a site in Basel in 1857, where they built a dyewood mill and a dye extraction plant. Two years later, they began the production of synthetic fuchsine. In 1901, they formed the public limited company Geigy and the name of the company was changed to J. R. Geigy Ltd in 1914.
In 1925, J. R. Geigy Ltd. began producing textile auxiliaries, an activity which Ciba took up in 1928.
In 1980, Ciba-Geigy set up the company, Ciba Vision, to enter the contact lens market.
In 1992 Ciba-Geigy agreed to pay New Jersey $62 million for illegal waste dumping.
In 1996 Ciba-Geigy merged with Sandoz, with the pharmaceutical and agrochemical divisions of both staying together to form Novartis. Other Ciba-Geigy and Sandoz businesses were spun off as independent companies. Notably, Ciba Specialty Chemicals was spun out as an independent company, and "Sandoz's Master Builders Technologies, a producer of chemicals for the construction industry, (was sold off) to SKW Trostberg A.G., a subsidiary of the German energy company Viag, and its North American corn herbicide business (was sold off) to the German chemical maker BASF A.G."
Sandoz (before formation of Novartis)
Before the 1996 merger with Ciba-Geigy to form Novartis, Sandoz Pharmaceuticals (Sandoz AG) was a pharmaceutical company headquartered in Basel, Switzerland (as was Ciba-Geigy), and was best known for developing drugs such as Sandimmune for organ transplantation, the antipsychotic Clozaril, Mellaril Tablets and Serentil Tablets for treating psychiatric disorders, and Cafergot Tablets and Torecan Suppositories for treating migraine headaches.
The Chemiefirma Kern und Sandoz ("Kern and Sandoz Chemistry Firm") was founded in 1886 by Alfred Kern (1850–1893) and Edouard Sandoz (1853–1928). The first dyes manufactured by them were alizarinblue and auramine. After Kern's death, the partnership became the corporation Chemische Fabrik vormals Sandoz in 1895. The company began producing the fever-reducing drug antipyrin in the same year. In 1899, the company began producing the sugar substitute, saccharin. Further pharmaceutical research began in 1917 under Arthur Stoll (1887–1971), who is the founder of Sandoz's pharmaceutical department in 1917. In 1918, Arthur Stoll isolates ergotamine from ergot; the substance is eventually used to treat migraine and headeaches and is introduced under the trade name Gynergen in 1921.
Between the World Wars, Gynergen (1921) and Calcium-Sandoz (1929) were brought to market. Sandoz also produced chemicals for textiles, paper, and leather, beginning in 1929. In 1939, the company began producing agricultural chemicals.
The psychedelic effects of lysergic acid diethylamide (LSD) were discovered at the Sandoz laboratories in 1943 by Arthur Stoll and Albert Hofmann. Sandoz began clinical trials and marketed the substance, from 1947 through the mid-1960s, under the name Delysid as a psychiatric drug, thought useful for treating a wide variety of mental ailments, ranging from alcoholism to sexual deviancy. Sandoz suggested in its marketing literature that psychiatrists take LSD themselves, to gain a better subjective understanding of the schizophrenic experience, and many did exactly that and so did other scientific researchers. The Sandoz product received mass publicity as early as 1954, in a Time Magazine feature. Research on LSD peaked in the 1950s and early 1960s. Sandoz withdrew the drug from the market in the mid-1960s. The drug became a cultural novelty of the 1960s after psychologist Timothy Leary at Harvard University began to promulgate its use for recreational and spiritual experiences among the general public.
Sandoz opened its first foreign offices in 1964.
In 1967, Sandoz merged with Wander AG (known for Ovomaltine and Isostar). Sandoz acquired the companies Delmark, Wasabröd (a Swedish manufacturer of crisp bread), and Gerber Products Company (a baby food company).
On 1 November 1986, a fire broke out in a production plant storage room, which led to Sandoz chemical spill and a large amount of pesticide being released into the upper Rhine river. This exposure killed many fish and other aquatic life.
In 1995, Sandoz spun off its specialty chemicals business to form Clariant. Subsequently, in 1997, Clariant merged with the specialty chemicals business that was spun off from Hoechst AG in Germany.
In 1996 Sandoz merged with Ciba-Geigy, with the pharmaceutical and agrochemical divisions of both staying together to form Novartis.
After the merger
In 1998, the company made headlines with its biotechnology licensing agreement with the University of California at Berkeley Department of Plant and Microbial Biology. Critics of the agreement expressed concern over prospects that the agreement would diminish academic objectivity, or lead to the commercialization of genetically modified plants. The agreement expired in 2003.
In 2003, Novartis organized all its generics businesses into one division, and merged some of its subsidiaries into one company, reusing the predecessor brand name of Sandoz.
In 2005, Novartis expanded its subsidiary Sandoz significantly though the US$8.29 billion acquisition of Hexal, one of Germany's leading generic drug companies, and Eon Labs, a fast-growing United States generic pharmaceutical company.
In 2006, Novartis acquired the California-based Chiron Corporation. Chiron formerly was divided into three units: Chiron Vaccines, Chiron Blood Testing, and Chiron BioPharmaceuticals. The biopharmaceutical unit was integrated into Novartis Pharmaceuticals, while the vaccines and blood testing units were made into a new Novartis Vaccines and Diagnostics division.
In 2009, Novartis reached an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry leader in this country and expand the Group's limited presence in this fast-growing market segment. This proposed acquisition will require government and regulatory approvals in China.
In 2010, Novartis offered to pay US $39.3 billion to fully acquire Alcon, the world's largest eye-care company, including a majority stake held by Nestlé. Novartis had bought 25% of Alcon in 2008. Novartis created a new division and called it Alcon, under which it placed its CIBA VISION subsidiary and Novartis Ophthalmics, which became the second-largest division of Novartis.
In 2011, Novartis acquired the medical laboratory diagnostics company Genoptix to "serve as a strong foundation for our (Novartis') individualized treatment programs".
In 2012, the Company cut ~2000 positions in the United States, most in sales, in response to anticipated revenue downturns from the hypertension drug Diovan, which was losing patent protection, and the realization that the anticipated successor to Diovan, Rasilez, was failing in clinical trials. The 2012 personnel reductions follow ~2000 cut positions in Switzerland and the United States in 2011, ~1400 cut positions in the United States in 2010, and a reduction of "thousands" and several site closures in previous years.
Also in 2012, Novartis became the biggest manufacturer of generic skin care medicine, after agreed to buy Fougera Pharmaceuticals for $1.525 billion in cash.
In 2013, Novartis was sued again by the US government, this time for allegedly bribing doctors for a decade so that their patients are steered towards the company's drugs.
In January 2014, Novartis announced plans to cut 500 jobs from its pharmaceuticals division.
In February 2014, Novartis announced that it has acquired CoStim Pharmaceuticals.
The company's global research operations, called "Novartis Institutes for BioMedical Research (NIBR)" have their global headquarters in Cambridge, Massachusetts, United States. Two research institutes reside within NIBR that focus on diseases in the developing world: Novartis Institute for Tropical Diseases, which works on tuberculosis, dengue, and malariam and Novartis Vaccines Institute for Global Health, which works on salmonella typhi (Typhoid Fever) and Shigella.
Novartis is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox project. The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.
Basel headquarters campus redesign
An ongoing Basel Campus Project has the aim to transform Novartis headquarters in Basel "from an industrial complex to a place of innovation, knowledge, and encounter". The pharmaceutical giant decided to transform the existing Sandoz office buildings and chemical factories of its headquarters in 2001.
The buildings gradually were demolished and replaced with works by architects and artists of international stature. Frank Gehry, Rafael Moneo, and from SANAA, Kazuyo Sejima and Ryue Nishizawa were among the architects and Jenny Holzer and Richard Serra among the artists. Marked diversity of forms now dominates the campus. Novel features and technologies were introduced by Gehry to conform to the building standards of the Swiss government that prohibit air-conditioning, while still selecting a contemporary style of massive use of glass exteriors. One adaptation by the architect includes the integration of a building vent, teepee-style, through the roof, which creates a chimney effect that draws cool air in at the lower levels and vents warmer air.
|Name||Indication(s) or drug type/class||Sales US$millions||Sales year||% Change||Notes|
|Aclasta / Reclast (zoledronic acid)||Osteoporosis||590||2012||-4%|
|Afinitor/Sertican/Zortress (everolimus)||Prevention of transplant rejection, various cancers||797||2012||80%|
|Anafranil (clomipramine)||Major depressive disorder, obsessive-compulsive disorder|
|Arcapta Neohaler/Onbrez Breezhaler (indacaterol)||COPD|
|Clozaril/Leponex (clozapine)||Treatment-resistant schizophrenia|
|Coartem/Riamet (artemether/lumefantrine)||Malaria (uncomplicated|
|Comtan (entacapone)||Parkinson's disease||530||2012||-14%|
|Eucreas/Galvus Met (vildagliptin/metformin)||Diabetes mellitus type 2|
|Exelon Patch (rivastigmine)||Alzheimer's disease||1,050||2012||-2%|
|Exjade (deferasirox)||Chronic iron overload||870||2012||2%|
|Famvir (famciclovir)||Herpes zoster and other Herpesvirus infection|
|Femara (letrozole)||Breast cancer||438||2012||-52%|
|Focalin (dexmethylphenidate)||ADHD||First US generics of Focalin became available in 2007 Focalin XR became available in 2012.|
|Foradil/Foradile (formoterol)||Asthma, COPD|
|Galvus (vildagliptin)||Diabetes mellitus type 2||910||2012||39%|
|Gilenya (fingolimod)||Multiple sclerosis||1,195||2012||142%|
|Gleevec/Glivec (imatinib)||Oncology, Chronic myelogenous leukemia||4,675||2012||0%|
|Ilaris (canakinumab)||Cryopyrin-associated periodic syndrome|
|Jakavi/Jakafi (ruxolitinib)||Myelofibrosis (of intermediate to high risk)|
|Lamisil (terbinafine)||Fungal infections|
|Lucentis (ranibizumab)||Age-related macular degeneration||2,398||2012||17%|
|Ludiomil (maprotiline)||Major depressive disorder|
|Myfortic (mycophenolic acid)||Prevention of transplant rejection||579||2012||12%|
|Navoban (tropisetron)||Chemotherapy-induced nausea and vomiting|
|Sandimmune/Neoral (ciclosporin)||Prevention of transplant rejection||821||2012||-9%|
|Signifor (Pasireotide)||Cushing's disease|
|Simulect (basiliximab)||Prevention of transplant rejection|
|Spersallerg (antazoline/tetrahydrozoline)||Allergic conjunctivitis|
|Stalevo (carbidopa/levodopa/entacapone)||Parkinson's disease|
|Tasigna (nilotinib)||Chronic myelogenous leukemia (first-line treatment)||998||2012||39%||NICE formulary approval, January 2012|
|Tegretol (carbamazepine)||Epilepsy, bipolar disorder||413||2007||6%|
|Termalgin (paracetamol)||Fever, mild pain|
|Tobi (tobramycin)||Prevention of Pseudomonas aeruginosa infection in cystic fibrosis||350 (US only)||2012||Teva introduced generic in the US in 2013|
|Tofranil (imipramine)||Major depressive disorder, enuresis|
|Trileptal (oxcarbazepine)||Epilepsy, bipolar disorder||690 (US only)||2007||Teva introduced generic in 2008|
|Tyzeca/Sebivo (telbivudine)||Hepatitis B|
|Visudyne (verteporfin)||Age-related macular degeneration (wet form)|
|Voltaren (diclofenac)||Acute pain, inflammatory disorders (such as rheumatoid arthritis)||759 (excl. OTC)||2012||-4%|
|Zometa (zoledronic acid)||Prevention of bone fractures in cancer patients||1,288||2012||-13%|
|Xolair (omalizumab)||Asthma (moderate to severe)||504||2012||4%|
|Zaditen (ketotifen)||Asthma, allergic conjunctivitis|
- Bialcol Alcohol
- Buckley's cold and cough formula
- Comtrex cold and cough
- Doan's pain relief
- Keri skin care
- Lamisil foot care
- Lipactin herpes symptomatic treatment
- Prevacid 24HR
In January 2009, the United States Department of Health and Human Services awarded Novartis a $486 million contract for construction of the first U.S. plant to produce cell-based influenza vaccine, to be located in Holly Springs, North Carolina. The stated goal of this program is the capability of producing 150,000,000 doses of pandemic vaccine within six months of declaring a flu pandemic.
- Interceptor (Milbemycin oxime), oral worm control product
- Sentinel Flavor Tabs (Milbemycin oxime, Lufenuron), oral flea control product
- Deramaxx (Deracoxib), oral treatment for pain and inflammation from osteoarthritis in dogs
- Capstar (Nitenpyram), oral tablet for flea control
- Milbemax (Milbemycin oxime, Praziquantel), oral worm treatment
- Program (Lufenuron), oral tablet for flea control
- Acatalk Duostar (Fluazuron, Ivermectin), tick control for cattle
- CLiK (Dicyclanil), blowfly control for sheep
- Denagard (Tiamulin)
- Fasinex (Triclabendazole)
Bioprotection (insect and rodent control)
- Actara (Thiamenthoxam)
- Atrazine (Atrazine)
- Larvadex (Cyromazine)
- Neporex (Cyromazine)
- Oxyfly (Lambda-cyhalothrin))
- Virusnip (Potassium monopersulfate)
Controversies and criticism
Challenge to India's patent laws
Novartis fought a seven year, controversial battle to patent Gleevec in India, and took the case all the way to the Indian Supreme Court, where the patent application was finally rejected. The patent application at the center of the case was filed by Novartis in India in 1998, after India had agreed to enter the World Trade Organization and to abide by worldwide intellectual property standards under the TRIPS agreement. As part of this agreement, India made changes to its patent law; the biggest of which was that prior to these changes, patents on products were not allowed, while afterwards they were, albeit with restrictions. These changes came into effect in 2005, so Novartis' patent application waited in a "mailbox" with others until then, under procedures that India instituted to manage the transition. India also passed certain amendments to its patent law in 2005, just before the laws came into effect, which played a key role in the rejection of the patent application.
The patent application claimed the final form of Gleevec (the beta crystalline form of imatinib mesylate).:3 In 1993, during the time India did not allow patents on products, Novartis had patented imatinib, with salts vaguely specified, in many countries but could not patent it in India. The key differences between the two patent applications, were that 1998 patent application specified the counterion (Gleevec is a specific salt - imatinib mesylate) while the 1993 patent application did not claim any specific salts nor did it mention mesylate, and the 1998 patent application specified the solid form of Gleevec - the way the individual molecules are packed together into a solid when the drug itself is manufactured (this is separate from processes by which the drug itself is formulated into pills or capsules) - while the 1993 patent application did not. The solid form of imatinib mesylate in Gleevec is beta crystalline.
As provided under the TRIPS agreement, Novartis applied for Exclusive Marketing Rights (EMR) for Gleevec from the Indian Patent Office and the EMR was granted in November 2003. Novartis made use of the EMR to obtain orders against some generic manufacturers who had already launched Gleevec in India. Novartis set the price of Gleevec at USD 2666 per patient per month; generic companies were selling their versions at USD 177 to 266 per patient per month. Novartis also initiated a program to assist patients who could not afford its version of the drug, concurrent with its product launch.
When examination of Novartis' patent application began in 2005, it came under immediate attack from oppositions initiated by generic companies that were already selling Gleevec in India and by advocacy groups. The application was rejected by the patent office and by an appeal board. The key basis for the rejection was the part of Indian patent law that was created by amendment in 2005, describing the patentability of new uses for known drugs and modifications of known drugs. That section, Paragraph 3d, specified that such inventions are patentable only if "they differ significantly in properties with regard to efficacy." At one point, Novartis went to court to try to invalidate Paragraph 3d; it argued that the provision was unconstitutionally vague and that it violated TRIPS. Novartis lost that case and did not appeal. Novartis did appeal the rejection by the patent office to India's Supreme Court, which took the case.
The Supreme Court case hinged on the interpretation of Paragraph 3d. The Supreme Court decided that the substance that Novartis sought to patent was indeed a modification of a known drug (the raw form of imatinib, which was publicly disclosed in the 1993 patent application and in scientific articles), that Novartis did not present evidence of a difference in therapeutic efficacy between the final form of Gleevec and the raw form of imatinib, and that therefore the patent application was properly rejected by the patent office and lower courts.
Although the court ruled narrowly, and took care to note that the subject application was filed during a time of transition in Indian patent law, the decision generated widespread global news coverage and reignited debates on balancing public good with monopolistic pricing, innovation with affordability etc.
Had Novartis won and gotten its patent issued, it could not have prevented generics companies in India from continuing to sell generic Gleevec, but it could have obligated them to pay a reasonable royalty under a grandfather clause included in India's patent law.
In reaction to the decision, Ranjit Shahani, vice-chairman and managing director of Novartis India Ltd was quoted as saying "This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options." He also said that companies like Novartis would invest less money in research in India as a result of the ruling. Novartis also emphasized that it continues to be committed to access to its drugs; according to Novartis, by 2013, "95% of patients in India—roughly 16,000 people—receive Glivec free of charge... and it has provided more than $1.7 billion worth of Glivec to Indian patients in its support program since it was started...."
"No" to free flu vaccines
In June 2009, Novartis declined to provide free vaccines to the poor in order to counter a current flu epidemic, saying developing nations or donor nations should cover the costs. Daniel Vasella, Novartis chief executive, told the Financial Times that he would consider offering discounted pricing to low-income nations, but unlike GlaxoSmithKline, would not offer vaccines for free.
Sexual discrimination class action from 5,600 current and former employees
On May 17, 2010, a jury in the United States District Court for the Southern District of New York awarded $3,367,250 in compensatory damages against Novartis, finding that the company had committed sexual discrimination against twelve female sales representatives and entry-level managers since 2002, in matters of pay, promotion, and treatment after learning that the employees were pregnant. Two days later (the trial was bifurcated so that the punitive damages verdict was argued and deliberated separately), the jury awarded punitive damages in the amount of $250 million, representing about 2% of Novartis' gross revenues for 2009. Normally punitive damages would be reduced to less than a 10:1 ratio, but the trial was for a group of named plaintiffs in a class action, who were representing a class of 5,600 class members. The jury was instructed to award compensatory damages just to the named plaintiffs, but to award punitive damages to the entire class. Once the court makes findings on compensatory damages for the remaining class members (which are estimated by plaintiffs' counsel at just under $1 billion), the $250 million is expected to satisfy the Supreme Court's single-digit ratio test for proportionality of compensatory to punitive damages.
Off-label marketing and other marketing violations
In September 2008, the U.S. Food and Drug Administration (FDA) sent a notice to Novartis Pharmaceuticals regarding its advertising of Focalin XR, an ADHD drug, in which the company overstated its efficacy while marketing to the public and medical professionals.
In 2005 federal prosecutors opened an investigation into Novartis' marketing of several drugs: Trileptal, an antiseizure drug; three drugs for heart conditions - Diovan (the company’s top-selling product), Exforge, and Tekturna; Sandostatin, a drug to treat a growth hormone disorder; and Zelnorm, a drug for irritable bowel syndrome. In September, 2010, Novartis agreed to pay US$422.5 million in criminal and civil claims and to enter into a Corporate Integrity Agreement with the US Office of the Inspector General. According to the New York Times "Federal prosecutors accused Novartis of paying illegal kickbacks to health care professionals through speaker programs, advisory boards, entertainment, travel and meals. But aside from pleading guilty to one misdemeanor charge of mislabeling in an agreement that Novartis announced in February, the company denied wrongdoing." In the same New York Times article, Frank Lichtenberg, a Columbia professor who receives pharmaceutical financing for research on innovation in the industry, said off-label prescribing was encouraged by the American Medical Association and paid for by insurers, but off-label marketing was clearly illegal. “So it’s not surprising that they would settle because they don’t have a legal leg to stand on."
In April 2013, federal prosecutors filed two lawsuits against Novartis under the False Claims Act for off-label marketing and kickbacks; in both suits, prosecutors are seeking treble damages. The first suit "accused Novartis of inducing pharmacies to switch thousands of kidney transplant patients to its immunosuppressant drug Myfortic in exchange for kickbacks disguised as rebates and discounts". In the second, the Justice Department joined a qui tam, or whistleblower, lawsuit brought by a former sales rep over off-label marketing of three drugs: Lotrel and Valturna (both hypertension drugs), and the diabetes drug, Starlix. Twenty-seven states, the District of Columbia and Chicago and New York also joined.
Fighting off-label prescribing of competitor's drug
Outside the US, Novartis markets the drug ranibizumab (trade name Lucentis), which is a monoclonal antibody fragment derived from the same parent mouse antibody as bevacizumab (Avastin). Both Avastin and Lucentis were created by Genentech which is owned by Roche; Roche markets Avastin worldwide, and also markets Lucentis in the US. Lucentis has been approved worldwide as a treatment for wet macular degeneration and other retinal disorders; Avastin is used to treat certain cancers. Because the price of Lucentis is much higher than Avastin, many ophthalmologists began having compounding pharmacies formulate Avastin for administration to the eye, and began treating their patients with Avastin. In 2011, four trusts of the National Health Service in the UK issued policies approving use and payment for administering Avastin for macular degeneration, in order to save money, even though Avastin had not been approved for that indication. In April 2012, after failing to persuade the trusts that it was uncertain whether Avastin was as safe and effective as Lucentis, and in order to retain the market for Lucentis, Novartis announced it would sue the trusts. However, in July Novartis offered significant discounts (kept confidential) to the trusts, and the trusts agreed to change their policy, and in November, Novartis dropped the litigation.
Valsartan data scandal in Japan
In the summer of 2013, two Japanese universities retracted several publications of clinical trials that purported to show that Valsartan (branded as Diovan) had cardiovascular benefits, when it was found that statistical analysis had been manipulated, and that a Novartis employee had participated in the statistical analysis but had not disclosed his relationship with Novartis but only his affiliation with Osaka City University, where he was a lecturer.  The scandal led to several Japanese hospitals to stop using the drug and media outlets to run reports on the scandal and issues with the pharmaceutical industry in Japan. In January 2014 Japan's Health Ministry filed a criminal complaint with the Tokyo public prosecutor's office against Novartis and an unspecified number of employees, for allegedly misleading consumers through advertisements that used the research to support the benefits of Diovan.
- "Annual Report 2010" (PDF). Novartis. Retrieved 27 January 2011.
- "Top 20 global corporations". IMS. Retrieved 2012-01-06.
- "The Pharmaceutical Industry in Figures - 2008 Edition" (PDF). European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Retrieved 2008-08-25.
- IFPMA Member List
- PhRMA Member List
- 2012 Novartis Group Annual Report
- Staff, EP Vantage. April 25, 2012 Novartis on track to become world's biggest drug maker
- Carolyn Gauntlett and Sarah Rickwood for IMS Health. 2013. The changing face of the top 10 pharmaceutical companies
- Melly Alazraki for Daily Finance. August 26th 2010 Novartis Completes Purchase of Alcon Majority Stake from Nestle
- Staff, Generics Bulletin. June 7, 2013 Novartis difference puts Sandoz in prime position
- Reuters, October 21, 2010 Biosimilars take off at Novartis generics unit
- Staff, Generics and Biosimilars Initiative, November 9, 2012 Sandoz starts phase III US trial for biosimilar epoetin alfa
- Eric Palmer for FiercePharma, October 11, 2013 Novartis whacks vaccine jobs as it eyes unit for disposal
- Staff and wire reports for the Journal Star (LIncoln, Nebraska) August 14, 2013 Novartis reviews business; analyst urges selling OTC unit
- Staff, WHO. Access to Medicine Index, 2012
- Donald G McNeil Jr for the New York Times. June 28, 2010 The Drug Industry: GlaxoSmithKline, Merck and Novartis Again Rank Highest on Access to Poor
- "Company history", corporate website (Novartis), novartis.com
- "Archive of Ciba, now a part of BASF: History". Ciba.com. Archived from the original on 2010-01-03. Retrieved 2013-05-27.
- Staff, The Mineralogical Record Biographical Archive. J.R. Geigy (1830-1917)
- "Textile auxiliaries" are in the class of specialty chemicals and "enable a processing operation in preparation, dyeing, printing, or finishing to be carried out more effectively or which is essential if a given effect is to be obtained. Certain Textile Auxiliaries are also required in order to produce special finishing effects such as wash & wear, water repellence, flame retardancy, aroma finish, anti odour, colour deepening etc." (from Handbook on Textile Auxiliaries, Dyes and Dye Intermediates Technology, by the NPCS Board of Consultants & Engineers. Asia Pacific Business Press Inc., 2009.
- Ciba Vision "About us" page
- By JOSEPH F. SULLIVANPublished: February 29, 1992 (1992-02-29). "Ciba to Pay New Jersey For Illegal Waste Dumping - New York Times". Nytimes.com. Retrieved 2013-04-29.
- Magnus Grimond for The Independent. March 8, 1996 Ciba-Geigy and Sandoz to merge into pounds 40bn giant
- Glenn Collins for the New York Times. March 7, 1996 2 Swiss Drug Giants In a Surprise Merger To Be 2d in World
- Lawrence M. Fisher for strategy + business. April 1, 1998 Post-Merger Integration: How Novartis Became No. 1
- Monday - Friday,8:30 - 17:00, GMT+1(Central European Time) (2010-12-15). "Company history". Novartis.com. Retrieved 2012-01-16.
- "Albert Hofmann, 102, Invented LSD - The New York Sun". Nysun.com. Retrieved 2013-10-23.
- US Patent 2,438,259
- "Albert Hofmann: LSD - My Problem Child: Use of LSD in Psychiatry". Flashback.se. Retrieved 2012-01-16.
- "Medicine: Dream Stuff". Time. June 28, 1954.
- Anna Bálint: Clariant clareant. The beginnings of a specialty chemicals company, Campus Verlag, Frankfurt am Main/New York 2012, ISBN 978-3-593-39374-2.
- Andrew Ross Sorkin for the New York Times. December 03, 1999 AstraZeneca and Novartis To Shed Agricultural Units Accessed May 27, 2013
- Staff, PRNewsWire. November 13, 2000. Syngenta Begins Trading on the New York Stock Exchange Accessed May 27, 2013
- Press Release, Novartis. January 21, 2003 Novartis to Unite Its Generics Businesses Under One Single Global Brand: Sandoz
- Emily Church for MarketWatch Feb. 21, 2005 Novartis in $8.29 billion generics deals: to buy Hexal and its U.S. division Eon Labs
- Novartis press release. April 19, 2006 Novartis acquisition of Chiron approved by Chiron shareholders
- Staff, Biosimilars News. August 15, 2011 Biosimilars approved in Europe
- Andrew Martin and Andrew Ross Sorkin for the New York Times. April 13, 2007 Nestlé Agrees to Buy Gerber From Novartis
- Novartis to expand its human vaccines presence in China[dead link]
- Thomasson, Emma (4 January 2010). "Novartis seeks to buy rest of Alcon for $39 billion". Reuters. Retrieved 4 January 2010.
- Novartis Press Release. April 08, 2011 Stronger together: Novartis and Alcon creating the global leader in eye care
- Maclucas, Neil (2011-01-24). "Novartis to Buy Genoptix for $470 Million". Health. The Wall Street Journal. Archived from the original on 2014-01-03.
- Associated Press (January 13, 2012), "Novartis to cut almost 2,000 US jobs this year", The Jakarta Post, jakartapost.com, retrieved January 15, 2012
- Reid, Katie (January 13, 2012), Hans-Juergen Peters and Mike Nesbit, ed., Novartis cuts 2,000 U.S. jobs after drug setback, Reuters, reuters.com, retrieved January 15, 2012
- "Novartis to Buy Fougera Pharmaceuticals for $1.5 Billion". The New York Times. May 2, 2012.
- Harris, Gardiner; Thomas, Katie (2013-04-01). "Top Court in India Rejects Novartis Drug Patent". New York Times. Retrieved 1 April 2013.
- "US sues Novartis again, says it bribed doctors for patents". Indian Express. Retrieved 2013-04-29.
- Tracy Staton (2014-01-21). "Novartis to cut 500 Swiss pharma jobs, then staff up in OTC, generics". FiercePharma. Retrieved 2014-02-19.
- "Novartis acquires CoStim Pharmaceuticals". Drug Store News. January 18, 2014. Retrieved February 19, 2014.
- Ross, Casey (2010-10-27). "Novartis doubles plan for Cambridge". Boston Globe. Retrieved 2010-10-31.
- Novartis Institutes for BioMedical Research Official SIte
- Innovation for the developing world
- Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. Essential Concepts in Toxicogenomics. Methods in Molecular Biology 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
- InnoMed PredTox Member Organizations (web page), InnoMed, archived from the original on 2008-09-26, retrieved 2008-08-25
- Innovative Medicines Initiative, ed. (2008), "IMI-GB-018v2-24042008-CallTopics.pdf" (PDF), IMI 1st Call 2008: Information Package (ZIP archive) (European Commission), retrieved 2012-01-16
- "Basel Campus Project". Novartis. Retrieved 2007-10-11.
- Novartis Top 20 Products Annual Sales (Novartis Website), accessed October 19, 2013
- Teva press release. January 30, 2007 Teva Receives Approval for Generic Focalin™ Tablets
- "IPCI: FDA Approves First Focalin XR ANDA; Positive Incremental Step Toward Approval and October Launch for IPCI".
- Novartis official 2007 product sales From Internet Archive; archive date November 13, 2007
- EMEA Approval for Pasireotide
- "FDA Approves Pasireotide for Cushing's Disease".
- "NICE Backs Novartis's Tasigna For CML, Rejects BMS's Sprycel", Wall Street Journal, 12 January 2012, online.wsj.com, retrieved 15 Jan 2012
- Teva press release. October 14, 2013 Teva Announces FDA Approval of Generic TOBI® in the United States
- Teva Press Release December 12, 2007 Teva Announces Approval of Generic Trileptal Tablets
- "US Department of Health and Human Services awards Novartis USD 486 million contract to build manufacturing facility for pandemic flu vaccine" (Press release). Novartis. January 15, 2009. Retrieved 2009-11-13.
- Gardiner Harris and Katie Thomas for the New York Times. April 1, 2013 Top court in India rejects Novartis drug patent
- Note: The Indian patent application No.1602/MAS/1998 does not appear to be publicly available. However according to the decision of the IPAB on 26 June 2009 (page 27) discussed below, "The Appellant’s application under the PCT was substantially on the same invention as had been made in India."
- Published PCT application WO1999003854
- Staff, European Medicines Agency, 2004. EMEA Scientific Discussion of Glivec
- US Patent 5,521,184
- Indian Supreme Court Decision paragraphs 5-6
- Novartis v UoI, para 8-9
- Shamnad Basheer for Spicy IP March 11, 2006 First Mailbox Opposition (Gleevec) Decided in India
- Staff, LawyersCollective. September 6, 2011 Novartis case: background and update – Supreme Court of India to recommence hearing
- R. Jai Krishna and Jeanne Whalen for the Wall Street Journal. April 1, 2013 Novartis Loses Glivec Patent Battle in India
- Intellectual Property Appellate Board decision dated 26 June 2009, p 149
- W.P. No.24759 of 2006
- "Supreme Court rejects bid by Novartis to patent Glivec".
- Novartis v UoI, Para 191
- Novartis v UoI, Para 24-25
- "How the Indian judgment will reverberate across the world".
- "Patented drugs must be priced smartly".
- Patent with a purpose, Prof. Shamnad Basheer, Indian Express, 3 April 2013
- Kevin Grogan for PharmaTimes. February 27, 2012 Novartis explains stance over India patent law challenge
- Berne Declaration. May 8, 2007 Short questions and answers about the court case initiated by Novartis in India
- Shift in Novartis Strategy, The Telegraph
- "Novartis says 'no' to free flu vaccines". Andrew Jack. Financial Times. June 15, 2009.
- Mark Hamblett (New York Law Journal) (2010-05-20). "Novartis Hit With $250 Million in Punitives in Gender Bias Case". law.com. ALM Media. Retrieved 2012-01-16.
- "Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules CII". Warning Letters. U.S. Food and Drug Administration (FDA). 2008-09-25. Retrieved 2009-08-05.
- Wilson, Duff (2010-09-30). "Novartis Settles Off-Label Marketing Case". NYTimes.com. Retrieved 2012-01-16.
- "Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, reaches settlement agreement with US Attorney's Office" (press release). Novartis. 2010-09-30. Media Releases. Retrieved 2012-01-16.
- "U.S. Sues Novartis Again, Accusing It of Kickbacks". New York Times. 2013-04-26. Retrieved 2013-04-27.
- "United States Files Complaint Against Novartis Pharmaceuticals Corp. for Allegedly Paying Kickbacks to Doctors in Exchange for Prescribing Its Drugs". The United States Department of Justice. 2013-04-26. Retrieved 2013-04-26.
- Andrew Pollack for the New York Times. April 28, 2011 Cheaper Drug to Treat Eye Disease Is Effective
- Jeffreys, Branwen (2012-05-06). "Using Avastin for eye condition wet AMD 'could save NHS £84m'". bbc.com. Retrieved 2012-05-06.
- Copley, Caroline; Hirschler, Ben (April 24, 2012), Potter, Mark, ed., Novartis challenges UK Avastin use in eye disease, Reuters, retrieved April 29, 2012
- Ben Adams for Pharmafile. July 26, 2012 Lucentis price cut ends PCT-Novartis dispute
- Ben Adams for Pharma Times. October 3, 2012. Novartis to drop legal case against NHS body
- Kana Inagaki for the Wall Street Journal. Aug. 11, 2013 Novartis Hit by Scandal Over Japanese Drug Studies: Probes Uncover Altered Research Data; Swiss Giant Stands by Heart Medicine Diovan
- Kana Inagaki for the Wall Street Journal. August 12, 2013. Novartis Drug Studies in Japan–Tracing Back the Questions
- "Japan Criminal Probe Could Spell More Trouble for Novartis". Wall Street Journal. January 10, 2014.
|Wikimedia Commons has media related to Novartis.|